Polaryx Therapeutics (NASDAQ:PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders ("LSDs"), announced that the late-breaking presentation of new data for PLX-200, an investigational therapy for the treatment of Krabbe disease (globoid cell leukodystrophy) at the 22nd Annual WORLDSymposium™, was given on February 6, 2026 in San Diego, Calif.

• No comments yet. Be the first to comment!